%0 Journal Article
%A Cortés-Ibáñez, Francisco O
%A Johnson, Theron
%A Mascalchi, Mario
%A Katzke, Verena
%A Delorme, Stefan
%A Kaaks, Rudolf
%T Serum-based biomarkers associated with lung cancer risk and cause-specific mortality in the German randomized Lung Cancer Screening Intervention (LUSI) trial.
%J Translational Lung Cancer Research
%V 12
%N 12
%@ 2218-6751
%C [Erscheinungsort nicht ermittelbar]
%I [Verlag nicht ermittelbar]
%M DKFZ-2024-00136
%P 2460 - 2475
%D 2023
%Z #EA:C020#LA:C020#
%X Lung cancer (LC) screening can be optimized using individuals' estimated risks of having a detectable lung tumor, as well as of mortality risk by competing causes, to guide decisions on screening eligibility, ideal screening intervals and stopping ages. Besides age, sex and smoking history, blood-based biomarkers may be used to improve the assessment of LC risk and risk of mortality by competing causes.In the German randomized Lung Screening Intervention Trial (LUSI), we measured growth/differentiation factor-15 (GDF-15), interleukin-6 (IL-6), C-reactive protein (CRP) and N-terminal pro-brain natriuretic protein (NT-proBNP), in blood serum samples collected at start of the trial. Participants in the computed tomography (CT)-screening arm also had a pulmonary function test. Regression models were used to examine these markers as predictors for impaired lung function, LC risk and mortality due to LC or other causes, independently of age, sex and smoking history.Our models showed increases in LC risk among participants with elevated serum levels of GDF-15 [odds ratio (OR)Q4-Q1 =2.47, 95
%K Serum biomarkers (Other)
%K lung cancer screening (LC screening) (Other)
%K lung function impairment (spirometry) (Other)
%K mortality (Other)
%K risk modeling (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:38205209
%2 pmc:PMC10775005
%R 10.21037/tlcr-23-548
%U https://inrepo02.dkfz.de/record/287029